Business
A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled
Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
- Published
- (2 h ago)
- Outlet
- CNBC Top News
- Section
- Business
- Length here
- Headline and 26-word snippet. The full article is at the source.
More from CNBC Top News and around the same time
Supermarket fridges are under attack in Europe — here's what's happeningEuropean supermarkets have become the center of another cyberattack, with hackers remotely heating fridges and spoiling food.Apple's John Ternus faces early test as global memory crisis hurts profitsIn John Ternus' first earnings report as CEO, Apple issued a gross margin forecast that disappointed Wall Street.Versant earnings beat expectations as digital platforms drive growthVersant posted third-quarter earnings that beat Wall Street expectations and reaffirmed its full-year guidance.Yum Brands earnings beat estimates, but cyclospora outbreak weighs on Taco BellTaco Bell's same-store sales declined as a Cyclospora outbreak tied to lettuce served at its restaurants weighed on traffic.Pfizer hikes full-year outlook, taps company veteran as new CFOPfizer announced that Cecile Guegan, who has held various leadership roles at the company over the last 20 years, stepped in as CFO this month.Midterm elections could jolt stocks if Democrats sweep CongressWall Street weighs how the 2026 midterms could affect stocks, Treasury yields, artificial intelligence, energy prices, banks, defense and healthcare.This page holds the headline and a short snippet as published by CNBC Top News, whose feed they came from. The story itself, the photography and the rights stay with them, and the button above goes straight to their site. We keep this page so the headline has a stable address and a record of when it ran.
